Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 in unresectable hepatocellular carcinoma with high arginine levels
NCT05317819Phase 3Recruiting
- Sponsor
- Polaris Group
- Start
- Mar 2022
- Primary completion
- Sep 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing ADI-PEG 20 with Placebo (2 arms). Primary endpoint: Overall Survival at 18 months. Started Mar 2022; status: recruiting.
02
Drugs
Pegargiminase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05317819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317819.